Professional
Added to YB: 2024-10-22
Pitch date: 2024-09-30
RARE [bullish]
Ultragenyx Pharmaceutical Inc.
-34.81%
current return
Author Info
No bio for this author
Company Info
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
Market Cap
$2.8B
Pitch Price
$55.58
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.05
P/E
-5.34
EV/Sales
5.22
Sector
Biotechnology
Category
growth
Baron Health Care Fund New Position: Ultragenyx Pharmaceutical Inc.
RARE: 4 approved drugs, 20%+ growth. Pipeline: Setrusumab (Phase 3, $1B+ potential) for Osteogenesis Imperfecta; GTX-102 for Angelman Syndrome shows promising early data, registrational study started; Wilson disease drug incoming. Multiple blockbuster opportunities could significantly boost revenue and profits.
Read full article (1 min)